SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : XOMA. Bull or Bear?
XOMA 32.22+4.9%3:59 PM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Bluegreen who wrote (7701)11/11/1998 11:52:00 AM
From: aknahow   of 17367
 
New page added to CF web site. The creator of this site is not endorsing any of the new treatments mentioned on this page. XOMA is mentioned only because it also has been involved in Phase I trials for CF. None of us know if these trials or BPI will be successful in the treatment of CF.

www3.nbnet.nb.ca

New meds for CF being studied

CPX
Discovered by researchers at the National Institutes of Health, CPX is being developed by SciClone
Pharmaceuticals Inc. in conjunction with the Cystic Fibrosis Foundation.
Being studied at 5 major CF centers in the US.
Targets the defective gene causing the disease. It should alter what the defective gene does, without
altering the gene itself.
Phase 1 trials have just finished. Phase 1 was to monitor the safety of the drug.
Phase 2 started in the Fall of 1998. Phase 2 will begin to measure whether the drug is effective.
CFF's site on this study (Added Nov. 10, 1998)
Phase 3 will come later on.
If it passes Phase 3, it can be submitted for approval to the Food and Drug Administration.
PA-1420 (polymyxin E1)
Pathogenesis has been granted a US Patent for it. It's a broad-spectrum gram-negative aerosolized
antibiotic now in preclinical development. It will be used to treat a number of chronic lung infections,
including those common in CF, bronchiectasis, ventilator-dependant and immuno-compromised
patients.
Gene Therapy
Glutathione
Phenylbutyrate
CFF's page on the Phase 1 part of this study (Added Nov. 10, 1998)
Duramycin
CFF's page on the Phase 1 part of this study (Added Nov. 10, 1998)
tobramycin
Administered IV to target a mutation in the gene that affects 3% of patients with CF. Not being used as
an antibiotic for the symptoms of CF, but for it's possible usefulness as a gene-assist therapy for this
specific class of mutations. This is being done at Emory University Egleston Cystic Fibrosis Center in
Atlanta, Georgia.
Neuprex by XOMA (can kill some gram-negative bacteria and may also make them more susceptible to
antibiotics):
Phase I study, in cooperation with the CFF (Added Nov. 10, 1998)

Back to my CF Page
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext